2022 AAPM 64th Annual Meeting
Back to session list

Session Title: Safety and Quality Improvements in Brachytherapy
Question 1: Question 1: For MRI-based GYN HDR brachytherapy, MRI sequence used in the planning is
Reference:1. Dimopoulos JC, Petrow P, Tanderup K, et al. Recommendations from Gynaecological (GYN) GEC‐ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol. 2012;103:113–122.
Choice A:a. T1
Choice B:b. contrast enhanced T1
Choice C:c. T2
Choice D:d. contrast enhanced T2
Question 2: Titanium needles cannot be used in MRI-IBT for which of the following reasons"?
Reference:1. Blumenfeld P, Hata N, DiMaio S, et al: Transperineal prostate biopsy under magnetic resonance image guidance: a needle placement accuracy study. J Magn Reson Imaging 26:688-94, 2007 2. Ladd ME, Erhart P, Debatin JF, et al: Biopsy needle susceptibility artifacts. Magn Reson Med 36:646-51, 1996
Choice A:Too thick in diameter.
Choice B:Not MRI compatible.
Choice C:Too expensive.
Choice D:No longer available in US.
Question 3: 3. For a given course of treatment, if a fraction is imported in one format (eg. from an ARIA database) and then a subsequent fraction is imported in a different format (e.g., DICOM), Aria will ensure that the number of fractions delivered matches the number of fractions in the treatment plan.
Reference:Reference: BRAVOS Instructions for Use 1.1MR2 EN.
Choice A:a. True
Choice B:b. False
Question 4: 4. For courses of treatment, an external beam treatment plan of TrueBeam and a Brachytherpy plan of Braovos can be opened at the same time for the same patient.
Reference:Reference: BRAVOS Instructions for Use 1.1MR2 EN.
Choice A:a. True
Choice B:b. False
Question 5: Question 5 Failure mode severity in HDR 192Ir brachytherapy may be scored using the following scale:
Reference:Mayadev et al. A failure modes and effects analysis study for gynecologic high-dose-rate brachytherapy. Brachytherapy 2015;14:866-875.
Choice A:Pain
Choice B:Richter
Choice C:C-weighted decibel
Choice D:Dosimetric
Choice E:Enhanced Fujita
Question 6: Question 6 The calibration uncertainty (k=1) for HDR 192Ir source strength as measured by the medical physicist with an ADCL-traceably calibrated reentrant well-type air ionization chamber is:
Reference:DeWerd et al. Uncertainties in photon brachytherapy dosimetry. A dosimetric uncertainty analysis for photon-emitting brachytherapy sources: Report of AAPM Task Group No. 138 and GEC-ESTRO. Med Phys 2011;38:782-801. Kirisits et al. Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM. Radiotherapy Oncol 2014;110:199-212.
Choice A:a. 0.5%
Choice B:b. 1.5%
Choice C:c. 3.0%
Choice D:d. 5.0%
Back to session list